Algeta's Alpharadin results even better than expected, analysis shows
This article was originally published in Scrip
Executive Summary
Algeta has completed survival analysis on updated clinical data generated from the hugely successful ALSYMPCA Phase III trial of Alpharadin (radium-223 chloride), and concluded that the drug works even better than earlier data showed.